Should we treat individuals homozygous for HFE p.Cys282Tyr with ferritin 300-1000 μg/L?

Affiliations

¹ Southern Iron Disorders Center, Birmingham, AL, USA; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Brookwood Medical Center, Birmingham, AL 35209, USA. Electronic address: ironmd@isp.com.

Editorial

James C Barton. Lancet Haematol. 2017 Dec.

. 2017 Dec;4(12):e569-e570.

doi: 10.1016/S2352-3026(17)30218-1.

¹ Southern Iron Disorders Center, Birmingham, AL, USA; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Brookwood Medical Center, Birmingham, AL 35209, USA. Electronic address: ironmd@isp.com.

No abstract available

Comment on

Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
Ong SY, Gurrin LC, Dolling L, Dixon J, Nicoll AJ, Wolthuizen M, Wood EM, Anderson GJ, Ramm GA, Allen KJ, Olynyk JK, Crawford D, Ramm LE, Gow P, Durrant S, Powell LW, Delatycki MB. Ong SY, et al. Lancet Haematol. 2017 Dec;4(12):e607-e614. doi: 10.1016/S2352-3026(17)30214-4. Lancet Haematol. 2017. PMID: 29195602 Clinical Trial.